Clinical analysis of lymphoma with lymphedema as the first manifestation

doi:10.3969/j.issn.1006-7795.2023.06.024

Abstract

Abstract: Objective To investigate the clinical features of lymphoma patients with the first symptom of lymphedema. Methods From August 2010 to February 2022, 12 patients with lymphoma who presentied with lymphedema as the first manifestation were selected as the observation group, and 20 patients with secondary lymphedema of the lower limbs after gynecological tumor surgery were selected as the control group. We collected the clinical characteristics of two groups of patients and analyze the clinical characteristics of lymphoma patients with lymphedema as the first manifestation. Results There were 12 cases with lymphoedema caused or aggravated by lymphoma, including 1 case with upper limb edema, 10 cases with lower limb edema, and 1 case with systemic edema. These patients are often accompanied by clinical symptoms such as weakness, emaciation, pain, lumps, and enlarged lymph nodes. The proportion of patients with abnormal tumor markers is 6/8, and the prevalence of anemia is 6/12. The positive rates of ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are 8/8, 8/8, and 3/3, respectively. The patients are diagnosed by pathological diagnosis and immunohistochemistry. There were significant differences between the two groups in course of disease, main and concomitant symptoms, past history, tumor markers, anemia, and imaging examinations(P<0.01). Conclusion Lymphoma associated malignant lymphedema is rare and the incidence is insidious. In order to avoid misdiagnosis and delayed treatment of lymphoma, we should actively identify cause of lymphedema during follow-up.

Key words: lymphedema, malignant lymphedema, lymphoma, clinical characteristics

CLC Number:

Hao Kun, Sun Yuguang, Li Bin, Xin Jianfeng, Zhang Li, Yu Chunkai, Wang Rengui, Shen Wenbin. Clinical analysis of lymphoma with lymphedema as the first manifestation[J]. Journal of Capital Medical University, 2023, 44(6): 1067-1073.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.06.024

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I6/1067

References

［1］Ruocco V, Brunetti G, Puca R V, et al. The immunocompromised district: a unifying concept for lymphoedematous, herpes-infected and otherwise damaged sites［J］. J Eur Acad Dermatol Venereol, 2009, 23(12): 1364－1373.
［2］Weissleder H, Schuchhardt C, Baumeister R G H. Lymphedema: diagnosis and therapy［M］. Germany: Kagerer Kommunikation, 1997.
［3］Soucek-Hadwiger B, Döller W. Secondary malignant lymphedema［J］. Wien Med Wochenschr, 2006, 156(9/10): 309－313.
［4］Ruocco V, Schwartz R A, Ruocco E. Lymphedema: an immunologically vulnerable site for development of neoplasms［J］. J Am Acad Dermatol, 2002, 47(1): 124－127.
［5］González-Vela M C, González-López M A, Val-Bernal J F, et al. Cutaneous diffuse large B-cell lymphoma of the leg associated with chronic lymphedema［J］. Int J Dermatol, 2008, 47(2): 174－177.
［6］Parthiban R, Kaler A K, Shariff S, et al. Squamous cell carcinoma arising from congenital lymphedema［J］. SAGE Open Med Case Rep, 2013, 1: 2050313X13496507.
［7］Gomes C A, Magalhães C B S, Soares C Jr, et al. Squamous cell carcinoma arising from chronic lymphedema: case report and review of the literature［J］. Sao Paulo Med J, 2010, 128(1): 42－44.
［8］Ely J W, Osheroff J A, Chambliss M L, et al. Approach to leg edema of unclear etiology［J］. J Am Board Fam Med, 2006, 19(2): 148－160.
［9］Földi M, Földi E, Stro-ssenreuther R H K, et al. Földi's textbook of lymphology: for physicians and lymphedema therapists［M］. 2nd ed. Mu-nchen: Urban & Fischer Verlag, 2006.
［10］孙蕾, 王华, 姜珏, 等. 淋巴瘤与转移淋巴结的超声弹性成像特征及其临床价值［J］. 现代肿瘤医学, 2019, 27(24): 4437－4440.
［11］Fleury L F F Jr, Sanches J A Jr. Primary cutaneous sarcomas［J］. An Bras Dermatol, 2006, 81(3): 207－221.
［12］何玲, 刘丽萍, 杨楠兰. 不同活检方式对淋巴瘤诊断价值的研究进展［J］. 现代肿瘤医学, 2022, 30(9): 1702－1706.
［13］Hawkins K A, Amorosi E L, Silber R. Unilateral leg edema. A symptom of lymphoma［J］. JAMA, 1980, 244(23): 2640－2641.
［14］Smith R D, Spittell J A, Schirger A. Secondary lymphedema of the leg: its characteristics and diagnostic implications［J］. JAMA, 1963, 185: 80－82.
［15］Jensen M R, Simonsen L, Karlsmark T, et al. Lymphoedema of the lower extremities--background, pathophysiology and diagnostic considerations［J］. Clin Physiol Funct Imaging, 2010, 30(6): 389－398.

[1]	Song Yanting, Chen Dong, Shang Jianfeng, Fang Wei, Gong Shanshan, Lian Guoliang, Zhang Zhe. Clinicopathology analysis of 21 cases in primary cardiac tumors in children [J]. Journal of Capital Medical University, 2023, 44(6): 1074-1080.
[2]	Luo Yi, Qin Qi, Wang Peihao, Guo Kangshun, Zhang Xinping, Cui Yong. Application and research progress of artificial intelligence combined with spectral diagnosis technology in the identification of lung cancer tissues [J]. Journal of Capital Medical University, 2023, 44(6): 1095-1102.
[3]	Liu Xiu, Li Wencai. Preliminary study on the effect of UNC0379 on the proliferation of glioma cells [J]. Journal of Capital Medical University, 2023, 44(5): 741-746.
[4]	Peng Yichen, Zheng Yi, Li Shenglan, Yu Jianyu, Lan Yanjie, Liu Xinrui, Chen Feng, Li Wenbin. Study of genes associated with aberrant methylation regulation in high-grade meningiomas [J]. Journal of Capital Medical University, 2023, 44(5): 747-752.
[5]	Yin Xue, Yu Minghang, Wang Xi, Chen Jinglong. Progresses on the mutation of SWI/SNF complex and its impact on immune checkpoint inhibitor therapy response in hepatocellular carcinoma [J]. Journal of Capital Medical University, 2023, 44(5): 768-774.
[6]	Yin Shuo, Chen Feng, Zheng Xiaohong, Zhang Weichunbai, Li Wenbin. Novel drug therapies promote the treatment progress of primary central nervous system lymphoma [J]. Journal of Capital Medical University, 2023, 44(5): 775-781.
[7]	Wan Yan, Liu Fang, Guo Shan, Wu Jian. Transcriptome sequencing and survival analysis of noncirrhotic hepatitis B viral（HBV）-related hepatocellular carcinoma [J]. Journal of Capital Medical University, 2023, 44(5): 811-820.
[8]	Xu Jingxing, Zhou Quan, Ying Jianming. Recent progress on immunotherapy for tumor microenvironment of triple negative breast cancer [J]. Journal of Capital Medical University, 2023, 44(5): 882-888.
[9]	Xiao Zeru, Yan Rui, Liang Ziwei, Ge Yang, An Guangyu. Major tobacco carcinogen benzo(a)pyrene induces infiltration of M2 type macrophages by upregulating cyclooxygenase-2 expression in esophageal squamous carcinoma [J]. Journal of Capital Medical University, 2023, 44(5): 753-761.
[10]	Tan Yubo, Suboyinuer Tuerhong, Huang Jing, Zhang Tingting, Liu Junjie, Shaya Mahati. The mechanism of miR-150 targeted regulation of IGF2BP2 on the malignant phenotype of liver cancer [J]. Journal of Capital Medical University, 2023, 44(5): 762-767.
[11]	Yu Jianyu, Zheng Yi, Li Wenbin. Bioinformatics analysis of hippocalcin like 1 expression and clinical prognosis in primary central nervous system lymphoma [J]. Journal of Capital Medical University, 2023, 44(5): 724-732.
[12]	Zheng Yi, Song Lairong, Xu Xiaoying, Wu Zhen, Li Xiaojie, Xie Lei, Chen Feng, Li Wenbin. Construction and application of the human glioblastoma cell line Y1203 [J]. Journal of Capital Medical University, 2023, 44(5): 733-740.
[13]	Ning Tingting, Wang Zhaoqing, Zhang Nan, Zhu Shengtao. Clinical importance of ACE2 expression in colon cancer and susceptibility of colon cancer cells to three human coronaviruses using ACE2 as their receptor [J]. Journal of Capital Medical University, 2023, 44(4): 663-668.
[14]	. Oncologic and functional outcomes after laparoscopic radical prostatectomy:10-years follow-up [J]. Journal of Capital Medical University, 2023, 44(3): 424-432.
[15]	Zhu Guangyi, Wang Runjin, Xiong Tianyu, Ye Xiaobo, Liu Zhanliang, Cao Fang, Lin Zhemin, Niu Yinong. Analysis of risk factors for second primary malignancies after radical prostatectomy for non-metastatic prostate cancer [J]. Journal of Capital Medical University, 2023, 44(3): 433-438.